EUVIMEDEUVIMED entdecken
Crossref

Osteosarcoma: A review

A.G. Nerkar

Current Trends in Pharmacy and Pharmaceutical Chemistry · 2021

DOI: 10.18231/j.ctppc.2021.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Trends in Pharmacy and Pharmaceutical Chemistry, 2021. Verfasst von A.G. Nerkar. Die Arbeit nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is a type of cancer with onset in late childhood and peak at early adolescence. OS is a typically is chemo sensitive cancer. The treatment modalities include neo-adjuvant and adjuvant therapies with definitive surgery. Permutations and combinations of chemotherapeutics agents have been used. However, in many clinical trial high dose methotrexate has been used as main drug with cisplatin and doxorubicin (MAP). In recent years, case studies have cited addition of fourth drug to the three drug regimen gives a detail of drug regimen being used over past years and discusses the successful treatment.

Zitieren

APA

Nerkar, A. (2021). Osteosarcoma: A review. Current Trends in Pharmacy and Pharmaceutical Chemistry. https://doi.org/10.18231/j.ctppc.2021.010

Vancouver

Nerkar A. Osteosarcoma: A review. Current Trends in Pharmacy and Pharmaceutical Chemistry. 2021. doi:10.18231/j.ctppc.2021.010

BibTeX
@article{Nerkar2021,
  author = {Nerkar, A.G.},
  title = {Osteosarcoma: A review},
  journal = {Current Trends in Pharmacy and Pharmaceutical Chemistry},
  year = {2021},
  doi = {10.18231/j.ctppc.2021.010}
}
Kostenlos starten →